Ultrasensitive Troponin-I Assay to Be Introduced at the AACC Clinical Lab Expo
By LabMedica International staff writers Posted on 01 Aug 2013 |
An advanced rapid assay for the heart attack biomarker troponin-I is being introduced to American cardiac researchers and clinicians at the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013.
Abbot Diagnostics (Abbot Park, IL, USA) will be demonstrating the ARCHITECT High Sensitive Troponin-I (hsTnI) assay at the Clinical Lab Expo. In a study recently completed at Brigham and Women’s Hospital (Boston, MA, USA) this test was compared to a fourth generation troponin T assay among 4,695 patients presenting with severe chest pain.
Results revealed that the ARCHITECT hsTnI assay could detect very low levels of troponin-I, which allowed doctors to evaluate whether or not patients were having a heart attack within two to four hours after presentation. Furthermore, the test was so sensitive that doctors were able to predict which patients presenting with symptoms of a heart attack, such as severe chest pain, were at a higher risk for having a heart attack up to 30 days later.
"This study adds to the clinical evidence confirming the advantages of Abbott’s high sensitive troponin test to provide more insight to clinicians about which patients are at greater risk for a future heart attack as compared to contemporary tests," said Dr. John Frels, divisional vice president, diagnostics research at Abbott Diagnostics. "This is important information for patient care because it may help doctors focus on the patients at greater risk for appropriate management."
The ARCHITECT hsTnI assay – already being marketed in Europe – was designed to run on Abbott’s automated ARCHITECT family of analyzers.
Related Links:
Abbot Diagnostics
Abbot Diagnostics (Abbot Park, IL, USA) will be demonstrating the ARCHITECT High Sensitive Troponin-I (hsTnI) assay at the Clinical Lab Expo. In a study recently completed at Brigham and Women’s Hospital (Boston, MA, USA) this test was compared to a fourth generation troponin T assay among 4,695 patients presenting with severe chest pain.
Results revealed that the ARCHITECT hsTnI assay could detect very low levels of troponin-I, which allowed doctors to evaluate whether or not patients were having a heart attack within two to four hours after presentation. Furthermore, the test was so sensitive that doctors were able to predict which patients presenting with symptoms of a heart attack, such as severe chest pain, were at a higher risk for having a heart attack up to 30 days later.
"This study adds to the clinical evidence confirming the advantages of Abbott’s high sensitive troponin test to provide more insight to clinicians about which patients are at greater risk for a future heart attack as compared to contemporary tests," said Dr. John Frels, divisional vice president, diagnostics research at Abbott Diagnostics. "This is important information for patient care because it may help doctors focus on the patients at greater risk for appropriate management."
The ARCHITECT hsTnI assay – already being marketed in Europe – was designed to run on Abbott’s automated ARCHITECT family of analyzers.
Related Links:
Abbot Diagnostics
Latest AACC 2013 News
- Beckman Coulter Launches Newest Version of Remisol Advance at AACC
- Beckman Coulter's New Solutions Demonstrated at 2013 AACC Annual Meeting
- Solutions Designed for Labs to Reduce Costs and Improve Productivity Showcased at the AACC Expo
- Latest Generation Random Analyzer System Unveiled at the AACC Clinical Lab Expo
- Customized Assays Assembled Using Digital Molecular Barcoding Chemistry
- Customized Monoclonal Antibody Design Highlighted at the AACC Clinical Lab Expo
- Advanced Hospital Robot Courier Debuts at the AACC Clinical Lab Expo
- Researchers Will Have Ready Access to Molecular Diagnostics Expertise at the AACC Clinical Lab Expo
- Hybrid Random Access Analyzer on Display at AACC's Clinical Lab Expo
- DCN Diagnostics and Asahi Kasei Fibers Launch Market Collaboration
- Quantitative Test for ß-Hydroxybutyrate Assesses Diabetic Ketoacidosis